Alnylam Pharmaceuticals, Inc.
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR V

Last updated:

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.

Status:
Application
Type:

Utility

Filling date:

23 Feb 2021

Issue date:

24 Jun 2021